Novo's Once-Weekly Insulin Treatment Part of a Transforming T2D Space

New data from Novo Nordisk's Phase IIIa ONWARDS 2 trial studying insulin icodec shows it is effective as a once-weekly treatment for Type 2 diabetes.

Insulin icodec differs from other basal insulin products currently on the market, as they require once-daily injections.